^
    5d
    Evaluating the Efficacy and Safety of Trilaciclib in Patients Receiving First-line Sintilimab Plus Chemotherapy for Advanced Driver Gene-negative Non-squamous Non-Small Cell Lung Cancer (ChiCTR2600117016)
    P=N/A, N=80, Not yet recruiting, Shengjing Hospital of China Medical University; Shengjing Hospital of China Medical University
    New trial
    |
    carboplatin • Tyvyt (sintilimab) • pemetrexed • Cosela (trilaciclib)
    5d
    A non-inferiority, randomized, controlled, multicenter, phase II clinical study was conducted to evaluate the efficacy and safety of triaciclib in the first-line treatment of advanced squamous non-small cell lung cancer with paclitaxel or albumin-paclitaxel combined with carboplatin and tislelizumab (ChiCTR2500115243)
    P2, N=196, Not yet recruiting, Dongguan People's Hospital; Dongguan People's Hospital
    New P2 trial
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Cosela (trilaciclib)
    8d
    the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib (clinicaltrials.gov)
    P2, N=41, Enrolling by invitation, Henan Cancer Hospital | Not yet recruiting --> Enrolling by invitation | Trial primary completion date: Apr 2025 --> Jan 2026
    Enrollment open • Trial primary completion date
    |
    Cosela (trilaciclib)
    3ms
    Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy. (PubMed, Cell Rep Med)
    Additionally, activated CD8+ T cells recruit and activate neutrophils, forming a positive feedback loop. Combining trilaciclib with anti-PD-1 antibodies presents a promising strategy for NSCLC treatment.
    Journal
    |
    CD8 (cluster of differentiation 8) • STING (stimulator of interferon response cGAMP interactor 1) • CD177 (CD177 Molecule)
    |
    Cosela (trilaciclib)
    3ms
    A Prospective Phase II Clinical Study of Trilaciclib for Preventing Myelosuppression in Patients with Locally Advanced Nasopharyngeal Carcinoma, Esophageal Carcinoma, or Cervical Carcinoma Undergoing Induction Chemotherapy Combined with Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy (ChiCTR2500110354)
    P2, N=161, Not yet recruiting, The First Affiliated Hospital, Air Force Medical University; The First Affiliated Hospital, Air Force Medical University
    New P2 trial
    |
    Cosela (trilaciclib)
    3ms
    A Prospective, Multicenter, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Patients with Locally Advanced Squamous Cell Lung Cancer Receiving Concurrent Chemoradiotherapy (ChiCTR2500109840)
    P2, N=32, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P2 trial
    |
    Cosela (trilaciclib)
    3ms
    A prospective, single-arm, exploratory Phase II clinical study to evaluate the efficacy and safety of Trilaciclib in the first-line treatment of locally advanced cervical cancer patients with paclitaxel combined with carboplatin and radiotherapy (ChiCTR2500108685)
    P=N/A, N=30, Not yet recruiting, Tianjin Cancer Hospital Airport Hospital; Tianjin Cancer Hospital Airport Hospital
    New trial
    |
    carboplatin • paclitaxel • Cosela (trilaciclib)
    3ms
    Efficacy and Safety of Trilaciclib in Myeloprotection during Chemotherapy for Pediatric Patients with Parameningeal Rhabdomyosarcoma with Meningeal Invasion (ChiCTR2500108628)
    P4, N=30, Not yet recruiting, Beijing Children’s Hospital, Capital Medical University; Beijing Children’s Hospital, Capital Medical University
    New P4 trial
    |
    Cosela (trilaciclib)
    4ms
    ToPCourT: Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, Wake Forest University Health Sciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • Cosela (trilaciclib)
    4ms
    Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy (clinicaltrials.gov)
    P1/2, N=123, Completed, G1 Therapeutics, Inc. | Terminated --> Completed | Phase classification: P1b/2a --> P1/2
    Trial completion • Phase classification
    |
    topotecan • Cosela (trilaciclib)
    4ms
    Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC (clinicaltrials.gov)
    P2, N=107, Completed, G1 Therapeutics, Inc. | Terminated --> Completed
    Trial completion
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Cosela (trilaciclib)
    5ms
    The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer (clinicaltrials.gov)
    P2, N=96, Not yet recruiting, The Second Affiliated Hospital of Shandong First Medical University
    New P2 trial
    |
    albumin-bound paclitaxel • Cosela (trilaciclib)